TCTP promotes glioma cell proliferation in vitro and in vivo via enhanced β-catenin/TCF-4 transcription

Neuro-Oncology

Volumn 16, Issue 2, 2014, Pages 217-227

  Gu, Xuefeng ^a   Yao, Lifen ^a   Ma, Guoda ^a   Cui, Lili ^a   Li, You ^b   Liang, Wandong ^c   Zhao, Bin ^a   Li, Keshen ^a  

^a GUANGDONG MEDICAL UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

^c WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

catenin; glioma; TCF 4; TCTP

Indexed keywords

BETA CATENIN; CYCLIN D1; KI 67 ANTIGEN; T CELL FACTOR PROTEIN; TEMOZOLOMIDE; TRANSCRIPTION FACTOR TCF 4; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN TISSUE; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL PROLIFERATION; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; GENE EXPRESSION; GENETIC TRANSCRIPTION; GLIOMA; GLIOMA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MULTIMODALITY CANCER THERAPY; NONHUMAN; ONCOGENE C MYC; OVERALL SURVIVAL; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; WNT SIGNALING PATHWAY;

GLIOMA; TCF-4; TCTP; Β-CATENIN;

ANIMALS; APOPTOSIS; BASIC HELIX-LOOP-HELIX LEUCINE ZIPPER TRANSCRIPTION FACTORS; BETA CATENIN; BLOTTING, WESTERN; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; HUMANS; IMMUNOENZYME TECHNIQUES; MICE; MICE, NUDE; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84893041373     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/not194     Document Type: Article

References (32)

1. Arcuri F, Papa S, Carducci A, et al. Translationally controlled tumor protein (TCTP) in the human prostate and prostate cancer cells: expression, distribution, and calcium binding activity. Prostate. 2004; 60(2):130-140.
2. Bommer UA, Thiele BJ. The translationally controlled tumour protein (TCTP). Int J Biochem Cell Biol. 2004;36(3):379-385.
3. Chen SH, Wu PS, Chou CH, et al. A knockout mouse approach reveals that TCTP functions as an essential factor for cell proliferation and survival in a tissue- or cell type-specific manner. Mol Biol Cell. 2007; 18(7):2525-2532.
4. Jung J, Kim HY, Kim M, Sohn K, Kim M, Lee K. Translationally controlled tumor protein induces human breast epithelial cell transformation through the activation of Src. Oncogene. 2011;30(19):2264-2274.
5. Lucibello M, Gambacurta A, Zonfrillo M, et al. TCTP is a critical survival factor that protects cancer cells from oxidative stress-induced cell-death. Exp Cell Res. 2011;317(17):2479-2489.
6. Telerman A, Amson R. The molecular programmeof tumour reversion: the steps beyond malignant transformation. Nat Rev Cancer. 2009; 9(3):206-216.
7. Rho SB, Lee JH, Park MS, et al. Anti-apoptotic protein TCTP controls the stability of the tumor suppressor p53. FEBS Lett. 2011;585(1):29-35.
8. Li F, Zhang D, Fujise K. Characterization of fortilin, a novel antiapoptotic protein. J Bio Chem. 2001;276(50):47542-47549.
9. Zhang D, Li F,Weidner D, Mnjoyan ZH, Fujise K. Physical and functional interaction between myeloid cell leukemia 1 protein (MCL1) and fortilin. The potential role of MCL1 as a fortilin chaperone. J Bio Chem. 2002;277(40):37430- 37438.
10. Yang Y, Yang F, Xiong Z, et al. An N-terminal region of translationally controlled tumor protein is required for its antiapoptotic activity. Oncogene. 2005;24(30):4778-4788.
11. Amson R, Pece S, Lespagnol A, et al. Reciprocal repression between P53 and TCTP. Nat Med. 2011;18(1):91-99.
12. Hsu YC, Chern JJ, Cai Y, Liu M, Choi KW. Drosophila TCTP is essential for growth and proliferation through regulation of dRheb GTPase. Nature. 2007;445(7129):785-788.
13. Dong X, Yang B, Li Y, Zhong C, Ding J. Molecular basis of the acceleration of the GDP-GTP exchange of human ras homolog enriched in brain by human translationally controlled tumor protein. J Biol Chem. 2009; 284(35):23754-23764.
14. Langdon JM, Vonakis BM, MacDonald SM. Identification of the interaction between the human recombinant histamine releasing factor/translationally controlled tumor protein and elongation factor-1 delta (also known as eElongation factor-1B beta). Biochimica et Biophysica Acta. 2004;1688(3):232- 236.
15. Tuynder M, Susini L, Prieur S, et al. Biological modelsandgenes of tumor reversion: cellular reprogramming through tpt1/TCTP and SIAH-1. Proc Natl Acad Sci USA. 2002;99(23):14976-14981.
16. Tsarova K, Yarmola EG, Bubb MR. Identification of a cofilin-like actin-binding site on translationally controlled tumor protein (TCTP). FEBS Lett. 2010;584(23):4756-4760.
17. Jung J, Kim M, Kim MJ, et al. Translationally controlled tumor protein interacts with the third cytoplasmic domain of Na,K-ATPase a subunit and inhibits the pump activity inHeLa cells. J Bio Chem. 2004; 279(48):49868-49875.
18. Koziol MJ, Garrett N, Gurdon JB. Tpt1 activates transcription of oct4 and nanog in transplanted somatic nuclei. Curr Biol. 2007;17(9):801-807.
19. Nelson WJ, Nusse R. Convergence of Wnt, b-catenin, and cadherin pathways. Science. 2004;303(5663):1483-1487.
20. Gumbiner BM. Regulation of cadherin-mediated adhesion in morphogenesis. Nature. 2005;6(8):622-634.
21. Clevers H. Wnt/b-catenin signaling in development and disease. Cell. 2006;127(3):469-480.
22. Brembeck FH, Rosario M. Birchmeier W. Balancing cell adhesion and wnt signaling. The key role of b-catenin. Curr. Opin. Genetics and Dev. 2006;16(1):51-59.
23. Thompson MD, Monga SP. Wnt/beta-catenin signaling in liver health and disease. Hepatology. 2007;45(5):1298-1305.
24. Cavard C, Colnot S, Audard V, et al. Wnt/beta-catenin pathway in hepatocellular carcinoma pathogenesis and liver physiology. Future Oncol. 2008;4(5):647-660.
25. Takigawa Y, Brown AM. Wnt signaling in liver cancer. Curr Drug Target. 2008;9(11):1013-1024.
26. Sinicrope FA, Ruan SB, Cleary KR, Stephens LC, Lee JJ, Levin B. bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. Cancer Res. 1995;15(55):237-241.
27. Yue X, LanF, YangW, et al. Interruption ofb-catenin suppresses the EGFR pathway by blockingmultiple oncogenic targets in human glioma cells. Brain Res. 2010;1366:27-37. doi: 10.1016/j.brainres.2010.10.032
28. Pu P, Zhang Z, Kang C, et al. Downregulation of Wnt2 and beta-catenin by siRNA suppresses malignant glioma cell growth. Cancer Gene Ther. 2009;16(4):351-361.
29. SareddyGR, Panigrahi M, Challa S, et al.Activation of Wnt/b-catenin/Tcf signaling pathway in human astrocytomas. Neurochem Int. 2009; 55(5):307-317.
30. Zhang J, Huang K, Shi Z, et al. High b-catenin/Tcf-4 activity confers glioma progression via direct regulation of AKT2 gene expression. Neuro-Oncology. 2011;13(6):600-609.
31. FuH,Cai J, Clevers H, et al.Agenome-wide screenfor spatially restricted expression patterns identifies transcription factors that regulate glial development. J Neurosci. 2009;29(36):11399-11408.
32. Tuynder M, Fiucci G, Prieur S, et al. Translationally controlled tumor protein is a target of tumor reversion. Proc Natl Acad Sci USA. 2004; 101(43):15364-15369.